SCHEMBL12021175

SCHEMBL12021175

CC(=O)N1C2CN(Cc3ccccc3)C(=O)[C@H](C)N2C(=O)CN1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 5/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ CACNA1G O43497 5/20 0.39
▸ CACNA1H O95180 5/20 0.39
▸ CACNA1I Q9P0X4 5/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ BRS3 P32247 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ PREP P48147 1/20 0.38
▸ ACE P12821 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750962 0.88 SMN1; SMN2 (0.45) SMN1; SMN2KMT2ACACNA1GCACNA1HCACNA1I
SCHEMBL397692 0.88 SMN1; SMN2 (0.45) SMN1; SMN2KMT2ACACNA1GCACNA1HCACNA1I
SCHEMBL14504287 0.75 CACNA1G (0.44) SMN1; SMN2KMT2ACACNA1GCACNA1HCACNA1I
SCHEMBL14620323 0.74 CACNA1G (0.43) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL13673303 0.73 KMT2A (0.52) SMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL400299 0.73 CACNA1I (0.49) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL14629510 0.72 CACNA1G (0.42) CACNA1GCACNA1HCACNA1ICYP3A4
SCHEMBL16623163 0.72 CYP3A4 (0.54) CYP3A4
SCHEMBL13369117 0.70 SIRT5 (0.49) CYP3A4
SCHEMBL14620166 0.70 CLPP (0.59) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150057283-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO CHOONGWAE PHARMA CORPORATION (KR) 2015-02-26 — — US disclosed
US-8318738-B2 Reverse-turn mimetics and method relating thereto CHOONGWAE PHARMA CORPORATION (KR) 2012-11-27 — — US disclosed
US-20110294797-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO CHOONGWAE PHARMA CORPORATION (KR) 2011-12-01 — — US disclosed
US-20110257185-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO CHOONGWAE PHARMA CORPORATION (KR) 2011-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057283-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO WNT1, APC, WNT3 BRD4 1041/4885SMN1; SMN2 4611/4885KMT2A 4111/4885
US-20110257185-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO WNT1, APC, WNT3 BRD4 1041/4885SMN1; SMN2 4611/4885KMT2A 4111/4885
US-20110294797-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO WNT1, APC, WNT3 BRD4 1041/4885SMN1; SMN2 4611/4885KMT2A 4111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback